🇺🇸 FDA
Pipeline program

tiotropium + olodaterol

1237.6

Phase 3 small_molecule completed

Quick answer

tiotropium + olodaterol for Pulmonary Disease, Chronic Obstructive is a Phase 3 program (small_molecule) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim
Indication
Pulmonary Disease, Chronic Obstructive
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials